GLRX2 and ovarian cancer: To test whether these effects were also seen in ovarian cancer cells, we first directly measured Fe-S cluster formation using a validated Fe-S cluster formation assay in which cells are transfected with two separate vectors, one encoding the N-terminal half of Venus fluorescent protein fused to the Fe-S-containing protein glutaredoxin2 (GRX2), and the second encoding the C-terminal half of Venus fluorescent protein fused to GRX217.